Brainomix has received FDA clearance for its new lung imaging product, Brainomix 360 e-Lung. This AI-powered software is designed to support the diagnosis and management of lung diseases, particularly idiopathic pulmonary fibrosis (IPF). It marks Brainomix's entry into the lung imaging sector after making a name in the stroke AI imaging field.

The software analyzes lung scans using imaging and AI algorithms to identify patterns of fibrosis and other abnormalities. Its key features include AI-infused imaging biomarkers specifically designed for the pulmonary field. 

Brainomix claims that the e-Lung could significantly expedite healthcare delivery and improve clinical outcomes for patients with lung disease. By employing AI-powered imaging, the solution could enhance healthcare professionals' ability to make informed diagnostic and treatment decisions, potentially leading to improved patient outcomes.

Brainomix is a UK-based biotechnology company specializing in developing AI-powered imaging biomarkers. The company offers several key products within its Brainomix 360 platform, which includes modules such as e-ASPECTS for automated stroke assessment on CT scans, e-CTA for evaluating blood vessel status, e-CTP for assessing brain perfusion, and e-Lung for diagnosis of lung diseases. The company’s entry into the lung imaging space is followed by its Brainomix 360 Stroke platform, commercialized in the US and Europe.